Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Rodrigues dos Santos, Catarina ^a,b,d   Fonseca, Isabel ^b,d   Dias, Sérgio ^c,d   de Almeida, J C Mendes ^b,d  

^a Gulbenkian Programme for Advanced Medical Education   (Portugal)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Breast cancer; LDL cholesterol; Tumor progression

Indexed keywords

CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KI 67 ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID; LIPOPROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATIENT SELECTION; PROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BREAST TUMOR; DISEASE COURSE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHOLESTEROL, LDL; DISEASE PROGRESSION; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84895488200     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-132     Document Type: Article

References (85)

1. Eurostat http://epp.eurostat.ec.europa.eu accessed on 27July2013.
2. Centers for Disease Control and Prevention http://www.cdc.gov accessed on 27 July 2013.
3. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK. Major causes of death among men and women in China. New Engl J Med 2005, 353(11):1124-1134. 10.1056/NEJMsa050467, 16162883.
4. World Health Organization http://www.who.int accessed on 27 July 2013.
5. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, Lyon, France: International Agency for Research on Cancer, http://globocan.iarc.fr/, accessed on 27 July 2013.
6. Jin F, Shu XO, Devesa SS, Zheng W, Blot WJ, Gao YT. Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972-89. Canc Causes Contr 1993, 4(4):355-360.
7. Smith D. Epidemiology of dyslipidemia and economic burden on the healthcare system. Am J Manag Care 2007, 13(Suppl 3):S68-S71.
8. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 2010, 327(5961):46-50. 10.1126/science.1174621, 20044567.
9. Babina IS DS, Nabi IR, Hopkins AM. Lipid rafts as master regulators of breast cancer cell function. Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways 2011, InTech, Gunduz M, Gunduz E, ISBN 978-953-307-714-7 2011.
10. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354(3):270-282. 10.1056/NEJMra050776, 16421368.
11. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004, 6(6):229-239. 10.1186/bcr932, 1064079, 15535852.
12. Steinhagen-Thiessen E, Bramlage P, Losch C, Hauner H, Schunkert H, Vogt A, Wasem J, Jockel KH, Moebus S. Dyslipidemia in primary care-prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2008, 7:31. 10.1186/1475-2840-7-31, 2572156, 18922160.
13. Antalis CJ, Arnold T, Rasool T, Lee B, Buhman KK, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat 2010, 122(3):661-670. 10.1007/s10549-009-0594-8, 19851860.
14. Antalis CJ, Uchida A, Buhman KK, Siddiqui RA. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin Exp Metastasis 2011, 28(8):733-741. 10.1007/s10585-011-9405-9, 21744083.
15. Pussinen PJ, Karten B, Wintersperger A, Reicher H, McLean M, Malle E, Sattler W. The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem J 2000, 349(Pt 2):559-566. 1221179, 10880355.
16. Danilo C, Gutierrez-Pajares JL, Mainieri MA, Mercier I, Lisanti MP, Frank PG. Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res 2013, 15(5):R87. 10.1186/bcr3483, 24060386.
17. Pan B, Ren H, Lv X, Zhao Y, Yu B, He Y, Ma Y, Niu C, Kong J, Yu F, Sun WB, Zhang Y, Willard B, Zheng L. Hypochlorite-induced oxidative stress elevates the capability of HDL in promoting breast cancer metastasis. J Transl Med 2012, 10:65. 10.1186/1479-5876-10-65, 3342142, 22462581.
18. Pan B, Ren H, He Y, Lv X, Ma Y, Li J, Huang L, Yu B, Kong J, Niu C, Zhang Y, Sun WB, Zheng L. HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. Clin Canc Res 2012, 18(5):1246-1256.
19. Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, Pan L, Li J, Yang L, Lv X, Shen X, Chen B, Zhang Y, Willard B, He Y, Zheng L. High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer 2012, 131(1):70-82. 10.1002/ijc.26341, 21805479.
20. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 2013, 342(6162):1094-1098. 10.1126/science.1241908, 24288332.
21. Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, Sotgia F, Lisanti MP, Frank PG. Role of cholesterol in the development and progression of breast cancer. Am J Pathol 2011, 178(1):402-412. 10.1016/j.ajpath.2010.11.005, 3069824, 21224077.
22. Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, LeRoith D. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013, 32(8):961-967. 10.1038/onc.2012.113, 22469977.
23. Kim EJ, Choi MR, Park H, Kim M, Hong JE, Lee JY, Chun HS, Lee KW, Yoon Park JH. Dietary fat increases solid tumor growth and metastasis of 4 T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice. Breast Cancer Res 2011, 13(4):R78. 10.1186/bcr2927, 3236342, 21834963.
24. Kitahara CM, de Gonzalez Berrington A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 2011, 29(12):1592-1598. 10.1200/JCO.2010.31.5200, 3082977, 21422422.
25. Wallace RB, Rost C, Burmeister LF, Pomrehn PR. Cancer incidence in humans: relationship to plasma lipids and relative weight. J Natl Cancer Inst 1982, 68(6):915-918.
26. Kaye JA, Meier CR, Walker AM, Jick H. Statin use, hyperlipidemia, and the risk of breast cancer. Br J Cancer 2002, 86(9):1436-1439. 10.1038/sj.bjc.6600267, 2375376, 11986777.
27. Emaus A, Veierod MB, Tretli S, Finstad SE, Selmer R, Furberg AS, Bernstein L, Schlichting E, Thune I. Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat 2010, 121(3):651-660. 10.1007/s10549-009-0603-y, 19882245.
28. Iso H, Ikeda A, Inoue M, Sato S, Tsugane S. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 2009, 125(11):2679-2686. 10.1002/ijc.24668, 19544528.
29. Hoyer AP, Engholm G. Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control 1992, 3(5):403-408. 10.1007/BF00051352, 1525320.
30. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005, 165(19):2264-2271. 10.1001/archinte.165.19.2264, 16246993.
31. Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control 1994, 5(6):501-509. 10.1007/BF01831377, 7827236.
32. Hiatt RA, Fireman BH. Serum cholesterol and the incidence of cancer in a large cohort. J Chron Dis 1986, 39(11):861-870. 10.1016/0021-9681(86)90034-2, 3793838.
33. Ha M, Sung J, Song YM. Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women. Cancer Causes Control 2009, 20(7):1055-1060. 10.1007/s10552-009-9301-7, 19184472.
34. Tornberg SA, Holm LE, Carstensen JM. Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure. Acta Oncol 1988, 27(1):31-37. 10.3109/02841868809090315, 3365352.
35. Vatten LJ, Foss OP. Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24,329 Norwegian women. Canc Res 1990, 50(8):2341-2346.
36. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Canc Epidemiol Biomarkers Prev 1997, 6(11):863-873.
37. Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjørge T, Borena W, Häggström C, Engeland A, Nagel G, Almquist M, Selmer R, Tretli S, Concin H, Hallmans G, Jonsson H, Stattin P, Ulmer H. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PloS One 2013, 8(1):e54242. 10.1371/journal.pone.0054242, 3553083, 23372693.
38. Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009, 10(2):109-121. 10.1038/nrg2481, 19139765.
39. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004, 96(15):1152-1160. 10.1093/jnci/djh216, 15292387.
40. Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008, 18(9):671-677. 10.1016/j.annepidem.2008.06.006, 2566531, 18794007.
41. Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem 2001, 34(1):71-76. 10.1016/S0009-9120(00)00200-9, 11239519.
42. Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A. Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem 2005, 268(1-2):19-24.
43. Kim Y, Park SK, Han W, Kim DH, Hong YC, Ha EH, Ahn SH, Noh DY, Kang D, Yoo KY. Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea. Canc Epidemiol Biomarkers Prev 2009, 18(2):508-515.
44. Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, Vogelman JH, Orentreich N. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Canc Epidemiol Biomarkers Prev 1998, 7(6):483-488.
45. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, Neuhouser ML, Parker DR, Shikany JM, Stefanick ML, Thomson CA, Rohan TE. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Canc Epidemiol Biomarkers Prev 2009, 18(7):2046-2053.
46. Rosato V, Bosetti C, Talamini R, Levi F, Montella M, Giacosa A, Negri E, La Vecchia C. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011, 22(12):2687-2692. 10.1093/annonc/mdr025, 21415236.
47. Boyd NF, McGuire V. Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer. J Natl Cancer Inst 1990, 82(6):460-468. 10.1093/jnci/82.6.460, 2313717.
48. Ferraroni M, Gerber M, Decarli A, Richardson S, Marubini E, de Crastes Paulet P, de Crastes Paulet A, Pujol H. HDL-cholesterol and breast cancer: a joint study in northern Italy and southern France. Int J Epidemiol 1993, 22(5):772-780. 10.1093/ije/22.5.772, 8282454.
49. Bani IA, Williams CM, Boulter PS, Dickerson JW. Plasma lipids and prolactin in patients with breast cancer. Br J Cancer 1986, 54(3):439-446. 10.1038/bjc.1986.195, 2001617, 3756079.
50. Hasija K, Bagga HK. Alterations of serum cholesterol and serum lipoprotein in breast cancer of women. Indian J Clin Biochem 2005, 20(1):61-66. 10.1007/BF02893044, 3454168, 23105496.
51. Lopez-Saez JB, Martinez-Rubio JA, Alvarez MM, Carrera CG, Dominguez Villar M, de Lomas Mier AG, Domenech C, Senra-Varela A. Metabolic profile of breast cancer in a population of women in southern Spain. Open Clin Cancer J 2008, 2:1-6. 2490599, 18665244.
52. Abdelsalam KE, Hassan IK, Sadig IA. The role of developing breast cancer in alteration of serum lipid profile. J Res Med Sci 2012, 17(6):562-565. 3634296, 23626635.
53. Owiredu WK, Donkor S, Addai BW, Amidu N. Serum lipid profile of breast cancer patients. Pak J Biol Sci 2009, 12(4):332-338. 10.3923/pjbs.2009.332.338, 19579966.
54. Yadav NK, Poudel B, Thanpari C, Chandra Koner B. Assessment of biochemical profiles in premenopausal and postmenopausal women with breast cancer. Asian Pac J Cancer Prev 2012, 13(7):3385-3388. 10.7314/APJCP.2012.13.7.3385, 22994765.
55. Potischman N, McCulloch CE, Byers T, Houghton L, Nemoto T, Graham S, Campbell TC. Associations between breast cancer, plasma triglycerides, and cholesterol. Nutr Cancer 1991, 15(3-4):205-215.
56. Knapp ML, al-Sheibani S, Riches PG. Alterations of serum lipids in breast cancer: effects of disease activity, treatment, and hormonal factors. Clin Chem 1991, 37(12):2093-2101.
57. Agurs-Collins T, Kim KS, Dunston GM, Adams-Campbell LL. Plasma lipid alterations in African-American women with breast cancer. J Cancer Res Clin Oncol 1998, 124(3-4):186-190.
58. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474. 10.1245/s10434-010-0985-4, 20180029.
59. NCCN Clinical Practice Guidelines in Oncology http://www.nccn.org accessed on 27 July 2013, NCCN.
60. WHO classification of tumours of the breas. 2012, 22-23. Lyon: IARC, Lakhani SR EI, Schnitt SJ, Tan PH, van de Vijver MJ.
61. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010, 7(5):e1000279. 10.1371/journal.pmed.1000279, 2876119, 20520800.
62. Kritz H, Zielinski C, Sinzinger H. Low cholesterol and cancer. J Clin Oncol 1996, 14(11):3043-3048.
63. Trompet S, Jukema JW, Katan MB, Blauw GJ, Sattar N, Buckley B, Caslake M, Ford I, Shepherd J, Westendorp RG, de Craen AJ. Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol 2009, 170(11):1415-1421. 10.1093/aje/kwp294, 19889709.
64. Costa JBM, Oliveira M, Gouveia M, Carneiro AV. Incidence and prevalence of hypercholesterolemia in Portugal: a systematic review. Part III. Portuguese Journal of Cardiology 2003, 22(6):829-836.
65. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Canc Res 2009, 11(3):R31.
66. Lund EB M, Hair B, Ward K, Andrews J, Bayakly A, Gabram S, O'Regan R, Eley J. A first report of incidence rates (Not Prevalence) by breast cancer subtypes. Cancer Res 2009, 69(Issue 24, Supplement 3):Abstract 3065.
67. Cortez-Dias N, Robalo Martins S, Belo A, Fiuza M, em nome dos Investigadores do Estudo V Characterization of lipid profile in primary health care users in Portugal. Portuguese Journal Of Cardiology 2013, 32(12):987-996. 10.1016/j.repc.2013.06.008, 24280078, em nome dos Investigadores do Estudo V.
68. Pina LC, Castro AR, Silva C. Tensão arterial em três distritos de Portugal FCS. Trabalhos de Conclusão de Graduação 2008, http://bdigital.ufp.pt accessed on 27 July 2013.
69. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96(10):1504-1513. 10.1038/sj.bjc.6603756, 2359936, 17453008.
70. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE, American Society of Clinical Oncology Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013, 31(7):961-965. 10.1200/JCO.2012.45.9859, 23129741, American Society of Clinical Oncology.
71. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Canc Res Treat 1996, 41(2):177-185.
72. Zielinski CC, Stuller I, Rausch P, Muller C. Increased serum concentrations of cholesterol and triglycerides in the progression of breast cancer. J Cancer Res Clin Oncol 1988, 114(5):514-518. 10.1007/BF00391503, 3182912.
73. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabol 2008, 7(1):11-20.
74. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, Penn LZ. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A 2010, 107(34):15051-15056. 10.1073/pnas.0910258107, 2930553, 20696928.
75. Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, Finetti P, Guille A, Larderet G, Viens P, Sebti S, Bertucci F, Birnbaum D, Charafe-Jauffret E. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem cells 2012, 30(7):1327-1337. 10.1002/stem.1122, 22605458.
76. Martin BJ, vGK A comparison of cholesterol uptake and storage in inflammatory and non inflammatory breast cancer cells. Int J Breast Cancer 2012, 2012. Article ID 412581, 10 pages accessed on 27 July 2013, vGK.
77. Pires LA, Hegg R, Freitas ER, Tavares ER, Almeida CP, Baracat EC, Maranhao RC. Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer. Braz J Med Biol Res 2012, 45(6):557-564. 10.1590/S0100-879X2012007500068, 3854302, 22570085.
78. Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, Niimi M, Miyauchi A, Wong NC, Ishida T. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Canc Res 2004, 64(4):1515-1521.
79. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140(1):49-61. 10.1016/j.cell.2009.11.027, 2885975, 20079333.
80. Mendis SPP, Norrving B. in Global Atlas on Cardiovascular Disease Prevention and Control 2011, Geneva: World Health Organization (in collaboration with the World Heart Federation and World Stroke Organization).
81. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 2008, 15(2):209-219. 10.1016/j.devcel.2008.06.012, 18694561.
82. Orr G, Hu D, Ozcelik S, Opresko LK, Wiley HS, Colson SD. Cholesterol dictates the freedom of EGF receptors and HER2 in the plane of the membrane. Biophys J 2005, 89(2):1362-1373. 10.1529/biophysj.104.056192, 1366621, 15908575.
83. Ross R. Atherosclerosis-an inflammatory disease. New Engl J Med 1999, 340(2):115-126. 10.1056/NEJM199901143400207, 9887164.
84. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6(7):508-519. 10.1038/nri1882, 16778830.
85. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. New Engl J Med 2012, 367(19):1792-1802. 10.1056/NEJMoa1201735, 23134381.